Our HEPATIQ™ software provides a precise index of liver disease severity by quantitative analysis of nuclear medicine liver-spleen images.


The HEPATIQ™ technology automates the Quantitative Liver Spleen Scan (QLSS™) that has been proven to be an accurate predictor of clinical outcomes in the recently concluded prospective seven year multi-center HALT-C trial of 1056 patients and A2ALL study for regeneration of liver function after an adult-to-adult liver donor liver transplant.


The HEPATIQ Software has been cleared by the Food and Drug Administration for sale in the U.S.A.